# Phase 3 Study to Evaluate Efficacy of Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS)

> **NCT02970162** · PHASE3 · COMPLETED · sponsor: **Catalyst Pharmaceuticals, Inc.** · enrollment: 26 (actual)

## Conditions studied

- Lambert-Eaton Myasthenic Syndrome

## Interventions

- **DRUG:** Amifampridine Phosphate
- **DRUG:** Placebo Oral Tablet

## Key facts

- **NCT ID:** NCT02970162
- **Lead sponsor:** Catalyst Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11
- **Primary completion:** 2017-10
- **Final completion:** 2017-10
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2018-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02970162

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02970162, "Phase 3 Study to Evaluate Efficacy of Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS)". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT02970162. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*